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Nuclear Signaling Pathways for 1,25-Oihydroxyvitamin O3 Are 
Controlled by the Vitamin A Metabolite, 9-cis-Retinoic Acid 
The vitamin A metabolite, 9-cis-retinoic acid, 
may be the effector molecule that controls which 
genes respond to the 7,25-dihydroxyvitamin D, 
receptor. 
This review was prepared by Renny T. 
Franceschi, Ph.D., at the Departments of Peri- 
odontics, Prevention and Geriatrics, School of 
Dentistry and Department of Biological Chernis- 
try, School of Medicine, University of Michigan, 
Ann Arbor, MI 48109-1078. 
Ever since E.V. McCollum’ first resolved cod liver 
oil into antirachitic “fat-soluble D” and growth- 
promoting “fat-soluble A” fractions, knowledge 
concerning the mechanism of action of these two 
nutrients has grown in parallel. We now know that 
both compounds are extensively metabolized to 
form one or more hormonelike compounds and, fur- 
thermore, that some of these metabolites regulate 
gene expression by interacting with specific nuclear 
receptors. A recent report by Carlberg and cowork- 
ers2 indicates an even more subtle relationship: the 
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vitamin A metabolite, 9-cis-retinoic acid, can alter 
the specificity of the 1,25-dihydroxyvitamin D, re- 
ceptor for regulatory DNA sequences in target 
genes. 
Receptors for 1,2S-dihydroxyvitamin D,, all- 
trans-retinoic acid, and 9-cis-retinoic acid are mem- 
bers of the nuclear hormone receptor superfamily, a 
gene family having at least 30 members, including 
receptors for the classic steroid hormones (estro- 
gen, progesterone, glucocorticoids, androgens, 
mineralocorticoids), thyroid hormone, and several 
others for which the activating ligand is unknown 
(also known as “orphan receptors”)., All family 
members exhibit sequence homology at protein and 
DNA levels and have a characteristic structure con- 
sisting of distinct hormone and DNA-binding do- 
mains and a transcriptional modulation domain. An- 
other feature common to this class of molecules is 
that they control gene expression by interacting 
with specific DNA sequences or regulatory ele- 
ments in control regions of target genes. The inter- 
action of the hormone:receptor complex with its re- 
sponse element either alone or in complex with 
other factors alters the overall DNA structure of the 
gene promoter so as either to stimulate or to inhibit 
transcription. 
Although all superfamily members share these 
characteristics, receptors for 1,25-dihydroxyvita- 
min D, (VDR), retinoic acid (RAR), and thyroid 
hormone (TR) also have some unique features not 
found in classic steroid receptors. Thus, steroid re- 
ceptors bind DNA as homodimers while the VDR, 
RAR, and TR can form heterodimers with an acces- 
sory nuclear factor. This factor was recently iden- 
tified as the receptor for 9-cis-retinoic acid, also 
called the retinoid X-receptor or RXR.4 RXR- 
containing heterodimers interact with regulatory 
DNA sequences having an inherently different 
structure from those recognized by classic steroid 
receptors. Although steroid receptors bind to palin- 
dromic DNA sequences (e.g., the estrogen re- 
sponse element, 5’-AGGTCANNNTGACCT 37, 
VDR, RAR, and TR heterodimers bind to directly 
repeating structures related to the estrogen re- 
sponse element half-site (i.e., the hexameric se- 
quence, AGGTCA). The number of spacer bases 
between this hexameric repeat is a major determi- 
nant of receptor binding specificity; a three-base 
pair (bp) spacer designates VDR:RAR binding (also 
called DR3 for direct repeat with a three bp spacer), 
four bp (DR4) for TR:RXR, and five bp (DR5) for 
RAR:RXR. This relationship is known as the 3-4-5 
rule.’ In addition to existing as RXR heterodimers, 
the VDR, RAR, TR, and RXR may, like classic 
steroid receptors, also form homodimers. These ho- 
modimers appear to bind different DNA sequences. 
For example, RXR homodimers bind to hexameric 
direct repeats with a one-bp spacer (DRl), whereas 
VDR homodimers may bind hexameric core se- 
quences in a variety of orientations other than DR3 
(see ref. 6 for review). 
These possible differences in DNA-binding be- 
havior between VDR:VDR homodimers and 
VDR:RXR heterodimers form the basis for the re- 
cent report by Carlberg et al. ,* in which two differ- 
ent types of 1,25-dihydroxyvitarnin D3 response el- 
ements (VDREs) were compared in terms of their 
ability to be stimulated by 1,25-dihydroxyvitamin 
D, in the presence or absence of the RXR and 9-cis- 
retinoic acid. The two VDREs chosen for compar- 
ison were from the 5’-regulatory regions of the 
genes for mouse osteopontin and human osteocal- 
cin. Both genes encode bone-related proteins 
whose synthesis is stimulated by 1,25-dihy- 
droxyvitamin D,. The osteopontin VDRE contains 
the sequence 5’-GGTTCANNNGGTTCA-3’, which 
is a DR3 structure and, therefore, a binding site 
for the VDR:RXR heterodimer. In contrast, the 
osteocalcin VDRE contains the sequence 5’- 
GGGTGANNNNNNGGGTGA-3’, a hexamer di- 
rect repeat with a six-bp spacer (i.e., a DR6 se- 
quence). 
Experiments used Drosophila SL-3 cells, which 
have no endogenous VDR or RXR. Cells were 
transfected with expression plasmids capable of di- 
recting the synthesis of VDR or RXR and a reporter 
plasmid containing the desired VDRE upstream to 
the chloramphenicol acetyltransferase (CAT) gene, 
which was under the control of the thymidine ki- 
nase (tk) promoter. By measuring CAT enzyme ac- 
tivity, the authors2 could determine if a particular 
VDRE was able to act as an enhancer of the tk 
promoter. When cells contained reporter plasmid 
with the osteopontin VDRE or related DR3 se- 
quences, 1,25-dihydroxyvitamin D, or 9-cis-retinoic 
acid conferred a twofold CAT induction when the 
appropriate VDR or RXR expression plasmid was 
cotransfected. If cells were transfected with both 
receptor expression plasmids and both hormones, a 
clear synergistic response was obtained. In con- 
trast, when cells were transfected with CAT re- 
porter plasmid containing the osteocalcin VDRE (a 
DR6 sequence), a large 1,25-dihydroxyvitamin D, 
induction of CAT was seen as long as cells were 
cotransfected with the VDR expression vector. Si- 
multaneous transfection with RXR and treatment 
with 9-cis-retinoic acid did not further enhance the 
vitamin D response. Similar results were obtained if 
the hexameric sequence of the osteocalcin VDRE 
was arranged as a palindrome without spacing or as 
an inverted palindrome with a 12-bp spacer. Similar 
overall results were obtained when osteopontin or 
osteocalcin VDRE reporter plasmids were trans- 
fected into the human MCF-7 cell line, which con- 
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tains endogenous VDR and RXR. These results 
show that the osteocalcin VDRE is maximally stim- 
ulated by the 1,25-dihydroxyvitamin D,:VDR com- 
plex in the absence of RXR, while the osteopontin 
VDRE requires both 1,25-dihydroxyvitamin 
D,:VDR and 9-cis-retinoic acid:RXR complexes. 
Further evidence for the selectivity of these two 
VDREs was obtained when receptor:DNA binding 
was examined by band shift assays. VDR and RXR 
prepared by in vitro translation were mixed with 
VDREs from the osteopontin and osteocalcin 
genes, and the formation of receptor:DNA com- 
plexes was measured by looking for reduced mobil- 
ity of labeled VDRE DNA after gel electrophoresis. 
When binding to the osteopontin VDRE was exam- 
ined, a prominent shifted species was only observed 
in the presence of both VDR and RXR. In contrast, 
the osteocalcin VDRE produced a shifted species 
when incubated with either VDR or RXR. No fur- 
ther enhancement of binding was observed when 
both receptors were present. In contrast to the re- 
sults obtained with transfection experiments, where 
CAT expression was only stimulated in the pres- 
ence of 1,25-dihydroxyvitamin D, and 9-cis-retinoic 
acid, RXR and VDR induced band shifting in the 
absence of ligand. 
It should be pointed out that these studies are 
somewhat artificial because responses to 1,25- 
dihydroxyvitamin D,, 9-cis-retinoic acid, and their 
receptors were measured using an artificial gene 
containing the relevant VDREs. One wonders 
whether intact osteopontin and osteocalcin genes 
would exhibit the same response as the CAT re- 
porter genes used in these experiments. If this 
proves to be the case, these studies show that the 
VDR can regulate at least two separate types of 
genes: 1) those containing VDREs regulated by 
VDR:VDR homodimers and 2) those responding to 
VDR:RXR heterodimers. Of even greater signifi- 
cance is the possibility that responses to retinoic 
acid and thyroid hormone are regulated by a similar 
mechanism. 
Because VDRs and RXRs are found in most 
cells, the presence or absence of 9-cis-retinoic acid 
likely determines which set of genes is regulated by 
1,25-dihydroxyvitamin D,. The isomerization of all- 
trans-retinoic to the 9-cis isomer occurs in several 
tissues, but details of its regulation are not known.’ 
One interesting possibility would be the demonstra- 
tion that 9-cis isomerase activity changes during cell 
differentiation or at critical periods during tissue 
morphogenesis, thereby altering the overall respon- 
siveness of cells to hormonal stimuli. In this way, 
9-cis-retinoic acid and RXRs could double the reg- 
ulatory potential of 1,25-dihydroxyvitamin D, and 
related hormones. 
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Hypercholesterolemia of Copper Deficiency Is Linked to Glutathione 
Metabolism and Regulation of Hepatic HMG-CoA Reductase 
Copper deficiency in rats causes hypercholester- 
olemia and increases in hepatic glutathione con- 
centration and HMG-CoA reductase activity. Pre- 
vention of the increase in hepatic glutathione 
abolished the other changes. 
This review was prepared by George E. 
Bunce, Ph.D., at the Department of Biochemis- 
try and Nutrition, Virginia Polytechnic Institute, 
Blacksburg, VA 24061. 
The occurrence of hypercholesterolemia as a con- 
sequence of copper deficiency in the rat was first 
reported by Klevay’ 20 years ago. Subsequent at- 
tempts to determine the biochemical basis of this 
phenomenon have demonstrated that copper defi- 
ciency does not impair cholesterol catabolism and 
rather, it increases the activity of the 
rate-controlling enzyme of cholesterol biosynthesis, 
3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGR).4,5 Because physiologic concentrations of 
copper do not inhibit this enzyme, its increase in 
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